Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trimer refers to a structural protein architecture consisting of three subunits, a configuration widely utilized in the development of recombinant fusion proteins and vaccines to mimic the native quaternary structure of biological targets. In oncology, the term is associated with **SCB-313**, a recombinant human TRAIL-Trimer fusion protein developed by Clover Biopharmaceuticals using their proprietary **Trimer-Tag** platform; this design aims to enhance the stability and potency of TRAIL (TNF-related apoptosis-inducing ligand) for treating malignant pleural effusions and peritoneal malignancies. In the field of vaccinology, Trimer identifies stabilized viral envelope proteins, most notably **Trimer 4571** (VRC-HIVRGP096-00-VP), a stabilized HIV-1 clade A envelope trimer developed by the NIH Vaccine Research Center to induce broadly neutralizing antibodies. The platform is also applied to COVID-19 vaccines, such as the **S-Trimer** (e.g., SCB-2019 or WestVac's recombinant XBB trimer), which presents the SARS-CoV-2 spike protein in its native trimeric state to optimize the immune response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Trimer.